Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

Abstract

At steady state, imatinib is insensitive to potent CYP3A4 inhibition and relies on alternate elimination pathways. For agents with complex elimination pathways that involve autoinhibition, interaction studies that are done after a single dose may not be applicable when drugs are administered chronically.